Lilly, ImmuNext in preclinical autoimmune pact

ImmuNext granted Lilly an exclusive, worldwide license to an undisclosed preclinical target to treat autoimmune diseases. The partners

Read the full 184 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE